2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
3168
Uterine Cervical Neoplasms
2191
Endometrial Neoplasms
1334
Breast Neoplasms
819
Fallopian Tube Neoplasms
808
Carcinoma, Ovarian Epithelial
772
Neoplasms
540
Colorectal Neoplasms
439
Carcinoma, Non-Small-Cell Lung
420
Uterine Cervical Dysplasia
376
Pancreatic Neoplasms
363
Stomach Neoplasms
354
Prostatic Neoplasms
318
Lung Neoplasms
315
Melanoma
289
Uterine Neoplasms
239
Peritoneal Neoplasms
238
Neoplasm Metastasis
238
Vulvar Neoplasms
229
Urinary Bladder Neoplasms
225
Esophageal Neoplasms
225
Head and Neck Neoplasms
222
Sarcoma
219
Carcinoma, Renal Cell
214
Recurrence
213
Colonic Neoplasms
210
Papillomavirus Infections
206
Triple Negative Breast Neoplasms
191
Squamous Cell Carcinoma of Head and Neck
177
Vaginal Neoplasms
147
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
Gynecologic
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled